Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome

T. Fujihara, Tsutomu Takeuchi, Kazuo Tsubota, N. Kayagaki, H. Yagita, K. Okumura, T. Abe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The aim of the study was to elucidate the involvement of Fas antigen in human autoimmune disease, by analysing serum levels of soluble Fas/APO1 protein in patients with various autoimmune diseases, including system lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Behcet's syndrome and Sjogren's syndrome (SjS). The levels of soluble Fas/APO-1 in sera were quantitated by a sandwich enzyme-linked immunosorbent assay. Soluble Fas/APO-1 levels were significantly increased in serum from patients with primary Sjogren's syndrome (1°SjS) compared with control subjects. However, no significant differences in soluble Fas/APO-1 levels were noted in patients with secondary Sjogren's syndrome (2°SjS) nor in patients with any of the other autoimmune diseases. The soluble Fas/APO-1 level in 1°SjS patients with extraglandular diseases was significantly higher than that in patients without extraglandular diseases. These results suggest that soluble Fas/APO-1 protein may play an important role in the pathogenesis of 1°SS.

Original languageEnglish
Pages (from-to)496-499
Number of pages4
JournalClinical Rheumatology
Volume17
Issue number6
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Sjogren's Syndrome
Serum
Autoimmune Diseases
CD95 Antigens
Dermatomyositis
Behcet Syndrome
Systemic Scleroderma
Rheumatoid Arthritis
Proteins
Enzyme-Linked Immunosorbent Assay

Keywords

  • Autoimmune disease
  • Enzyme-linked immunosorbent assay
  • Sjogren's syndrome
  • Soluble Fas/APO-1 protein

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Fujihara, T., Takeuchi, T., Tsubota, K., Kayagaki, N., Yagita, H., Okumura, K., & Abe, T. (1998). Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome. Clinical Rheumatology, 17(6), 496-499.

Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome. / Fujihara, T.; Takeuchi, Tsutomu; Tsubota, Kazuo; Kayagaki, N.; Yagita, H.; Okumura, K.; Abe, T.

In: Clinical Rheumatology, Vol. 17, No. 6, 1998, p. 496-499.

Research output: Contribution to journalArticle

Fujihara, T, Takeuchi, T, Tsubota, K, Kayagaki, N, Yagita, H, Okumura, K & Abe, T 1998, 'Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome', Clinical Rheumatology, vol. 17, no. 6, pp. 496-499.
Fujihara, T. ; Takeuchi, Tsutomu ; Tsubota, Kazuo ; Kayagaki, N. ; Yagita, H. ; Okumura, K. ; Abe, T. / Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome. In: Clinical Rheumatology. 1998 ; Vol. 17, No. 6. pp. 496-499.
@article{8f00ae59b2b04dcfa443cf7f0119810e,
title = "Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome",
abstract = "The aim of the study was to elucidate the involvement of Fas antigen in human autoimmune disease, by analysing serum levels of soluble Fas/APO1 protein in patients with various autoimmune diseases, including system lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Behcet's syndrome and Sjogren's syndrome (SjS). The levels of soluble Fas/APO-1 in sera were quantitated by a sandwich enzyme-linked immunosorbent assay. Soluble Fas/APO-1 levels were significantly increased in serum from patients with primary Sjogren's syndrome (1°SjS) compared with control subjects. However, no significant differences in soluble Fas/APO-1 levels were noted in patients with secondary Sjogren's syndrome (2°SjS) nor in patients with any of the other autoimmune diseases. The soluble Fas/APO-1 level in 1°SjS patients with extraglandular diseases was significantly higher than that in patients without extraglandular diseases. These results suggest that soluble Fas/APO-1 protein may play an important role in the pathogenesis of 1°SS.",
keywords = "Autoimmune disease, Enzyme-linked immunosorbent assay, Sjogren's syndrome, Soluble Fas/APO-1 protein",
author = "T. Fujihara and Tsutomu Takeuchi and Kazuo Tsubota and N. Kayagaki and H. Yagita and K. Okumura and T. Abe",
year = "1998",
language = "English",
volume = "17",
pages = "496--499",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "6",

}

TY - JOUR

T1 - Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome

AU - Fujihara, T.

AU - Takeuchi, Tsutomu

AU - Tsubota, Kazuo

AU - Kayagaki, N.

AU - Yagita, H.

AU - Okumura, K.

AU - Abe, T.

PY - 1998

Y1 - 1998

N2 - The aim of the study was to elucidate the involvement of Fas antigen in human autoimmune disease, by analysing serum levels of soluble Fas/APO1 protein in patients with various autoimmune diseases, including system lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Behcet's syndrome and Sjogren's syndrome (SjS). The levels of soluble Fas/APO-1 in sera were quantitated by a sandwich enzyme-linked immunosorbent assay. Soluble Fas/APO-1 levels were significantly increased in serum from patients with primary Sjogren's syndrome (1°SjS) compared with control subjects. However, no significant differences in soluble Fas/APO-1 levels were noted in patients with secondary Sjogren's syndrome (2°SjS) nor in patients with any of the other autoimmune diseases. The soluble Fas/APO-1 level in 1°SjS patients with extraglandular diseases was significantly higher than that in patients without extraglandular diseases. These results suggest that soluble Fas/APO-1 protein may play an important role in the pathogenesis of 1°SS.

AB - The aim of the study was to elucidate the involvement of Fas antigen in human autoimmune disease, by analysing serum levels of soluble Fas/APO1 protein in patients with various autoimmune diseases, including system lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Behcet's syndrome and Sjogren's syndrome (SjS). The levels of soluble Fas/APO-1 in sera were quantitated by a sandwich enzyme-linked immunosorbent assay. Soluble Fas/APO-1 levels were significantly increased in serum from patients with primary Sjogren's syndrome (1°SjS) compared with control subjects. However, no significant differences in soluble Fas/APO-1 levels were noted in patients with secondary Sjogren's syndrome (2°SjS) nor in patients with any of the other autoimmune diseases. The soluble Fas/APO-1 level in 1°SjS patients with extraglandular diseases was significantly higher than that in patients without extraglandular diseases. These results suggest that soluble Fas/APO-1 protein may play an important role in the pathogenesis of 1°SS.

KW - Autoimmune disease

KW - Enzyme-linked immunosorbent assay

KW - Sjogren's syndrome

KW - Soluble Fas/APO-1 protein

UR - http://www.scopus.com/inward/record.url?scp=0031648730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031648730&partnerID=8YFLogxK

M3 - Article

C2 - 9890678

AN - SCOPUS:0031648730

VL - 17

SP - 496

EP - 499

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 6

ER -